• VRXA share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of VRXA shares has decreased $0.20 since the market last closed. This is a 10.20% drop.

  • Closed at $1.76.

    The stock has since risen $0.03 in after-hours trading.

Key terms

About VRXA

Veraxa Biotech Holding AG engages in operating an oncology-focused biotechnology company, which is the Veraxa Biotech AG (Company). The Company focuses on the development of novel antibody-based drug platforms for the treatment of cancer. The company was founded on June 25, 2025 and is headquartered in Zurich, Switzerland.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $55.66M

    A market capitalization up to $300 million places VRXA in the micro-capitalization category.

Key terms

Smart score

Latest VRXA news

Jul 30, 2026 1:30pm ET VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform by TipRanks Jul 29, 2026 1:00pm ET VERAXA Biotech (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms by TipRanks Jul 28, 2026 1:00pm ET VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures by TipRanks Jul 27, 2026 2:30pm ET VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration by TipRanks Jul 27, 2026 7:20am ET Veraxa Biotech advances VXA-222 following milestone in OmniAb pact by TipRanks Jul 24, 2026 1:00pm ET VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer by TipRanks Jul 23, 2026 12:30pm ET VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany by TipRanks Jul 23, 2026 7:36am ET Veraxa Biotech appoints Christoph Erkel as chief scientific officer by TipRanks Jul 20, 2026 1:00pm ET VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform by TipRanks Jul 15, 2026 1:30pm ET Why VERAXA Biotech (NASDAQ: VRXA) Could Benefit More Than Others From AI’s Growing Impact on Drug R&D by TipRanks Jul 13, 2026 1:30pm ET VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development by TipRanks Jul 13, 2026 7:25am ET Veraxa Biotech announces BiTAC pipeline collaboration with Ardigen by TipRanks Jul 10, 2026 4:10pm ET Veraxa CFO Torsten Burgermeister steps down, Carl von Halem named interim CFO by TipRanks Jul 09, 2026 1:00pm ET VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership by TipRanks Jul 07, 2026 12:30pm ET VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition by TipRanks Jul 06, 2026 1:00pm ET VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy by TipRanks Jul 06, 2026 9:15am ET Veraxa Biotech provides pipeline and partnering strategy update by TipRanks Jul 02, 2026 1:00pm ET VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program by TipRanks Jul 02, 2026 7:30am ET Veraxa Biotech initiates cell line development for BiTAC T-cell engager program by TipRanks Jul 01, 2026 1:30pm ET Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals by TipRanks Jun 25, 2026 2:30pm ET VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline by TipRanks Jun 24, 2026 2:00pm ET VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline by TipRanks Jun 24, 2026 7:10am ET Veraxa Biotech expands R&D site in Germany by TipRanks Jun 22, 2026 11:30am ET VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention by TipRanks Jun 18, 2026 7:21am ET Veraxa Biotech establishes in vitro proof-of-concept for BiTAC-ADC platform by TipRanks Jun 16, 2026 11:10am ET Veraxa Biotech AG trading resumes by TipRanks Jun 16, 2026 11:00am ET Veraxa Biotech AG trading halted, volatility trading pause by TipRanks Jun 15, 2026 11:25am ET Voyager Acquisition Corp trading resumes by TipRanks Jun 15, 2026 11:20am ET Voyager Acquisition Corp trading halted, volatility trading pause by TipRanks
Jul 29, 2026 7:00am ET VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates by GlobeNewswire Jul 27, 2026 7:00am ET VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb by GlobeNewswire Jul 24, 2026 4:05pm ET VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth by GlobeNewswire Jul 23, 2026 7:00am ET VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio by GlobeNewswire Jul 20, 2026 7:00am ET VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan by GlobeNewswire Jul 13, 2026 7:00am ET VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline by GlobeNewswire Jul 10, 2026 4:05pm ET VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister by GlobeNewswire Jul 06, 2026 7:00am ET VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines by GlobeNewswire Jul 02, 2026 7:00am ET VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program by GlobeNewswire Jun 24, 2026 7:00am ET VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development by GlobeNewswire Jun 18, 2026 7:00am ET VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026 by GlobeNewswire

VRXA Financials

1-year income & revenue

  • VRXA total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Net income: $8.99M (1Y), $180.50K (Q1)

    Net Income increased 117.06% since last year and decreased 89.42% since last quarter.

  • Earnings per share: $0.28 (1Y), $0.01 (Q1)

    EPS increased 116.95% since last year and decreased 87.2% since last quarter.

Key terms

VRXA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VRXA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range
  • How competitors are chosen

    VRXA's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $55.66M

    A market capitalization up to $300 million places VRXA in the micro-capitalization category.

Key terms

Latest investing news